TPTatiana V. Petrova

Tatiana V. Petrova

*This is an algorithmically generated author record based on publicly available information.

Tatiana V. Petrova has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandra V. Kanygina

    LOPUKHIN FRCC PCM, Moscow, Russia

    1 shared publication
  • Daria V. Kuznetzova

    LOPUKHIN FRCC PCM, Moscow, Russia

    1 shared publication
  • Elena A. Zerkalenkova

    Dmitry Rogachev National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

    1 shared publication
  • Elena Ivanovna Sharova

    Medical Genomics Laboratory, Lopukhin Federal Research and Clinical Center of Physical, Chemical Medicine of the Federal Medical Biological Agency, Moscow 119435, Russia

    1 shared publication
  • Liubov O. Skorodumova

    LOPUKHIN FRCC PCM, Moscow, Russia

    1 shared publication
  • Svetlana E. Varlamova

    The Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russia

    1 shared publication

Latest Publications

  • Open Access

    Latent EBV reactivation drives aberrant B-cell proliferation during ex vivo tumor-infiltrating lymphocyte expansion from EBV-negative rectal cancer tumor tissue

    by Tatiana V. Petrova, Daria V. Kuznetzova, Alexandra V. Kanygina, Liubov O. Skorodumova, Viktor A. Ivanov, Tatiana A. Astrelina, Svetlana E. Varlamova, Elena A. Zerkalenkova, Elena I. Sharova

    Recent studies underscore herpesvirus-associated risks, especially HHV6 and Epstein–Barr virus (EBV), in CAR-T and tumor-infiltrating lymphocyte (TIL) therapies, partly due to ex vivo cell manipulation. EBV-driven B cell outgrowth can occur during TIL expansion, and EBV-transformed B cells may exert immunomodulatory functions, potentially impacting TIL therapy efficacy and safety — areas that remain underexplored. Here, we characterized a spontaneously arising wild-type EBV-transformed B cell line, lcl_burn0214, established during ex vivo culture of a tumor specimen from a rectal cancer patient who was EBV-negative. The lcl_burn0214 cell line has undergone 70 passages and was confirmed as a monoclonal B cell line of patient origin via HLA genotyping, immunophenotyping (CD19, CD20), B cell receptor clonotype analysis. RNA-seq analysis revealed that lcl_burn0214’s gene expression closely resembles that of lymphoblastoid cells ( r = 0.88) rather than malignant B lymphomas. In immunocompromised mice, lcl_burn0214 exhibited limited tumorigenicity. Autologous TILs were negative for B cells and exhibited a strong interferon-gamma response in the ELISPOT assay during coculture with lcl_burn0214 or with the EBV peptide pool (1000–1800 spots per million of TILs). Our findings underscore the importance of monitoring TIL products for EBV-positive B cell contamination during manufacturing to ensure safety and therapeutic efficacy even for EBV-negative patients.